Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 5, 2010, Pages 906-916

  Janneh, Omar ^a,b   Bray, Patrick G ^c   Jones, Elizabeth ^b   Wyen, Christoph ^d   Chiba, Peter ^e   Back, David J ^b   Khoo, Saye H ^b  

^a Faculty of Engineering and Computing   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atazanavir; Lopinavir; Ritonavir; Saquinavir; Transporters

Indexed keywords

ATAZANAVIR; FUROSEMIDE; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; RITONAVIR; SAQUINAVIR; TARIQUIDAR; VERLUKAST; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; TRITIUM;

ARTICLE; CD4+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; ISOTOPE LABELING; LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; CELL CULTURE; DRUG EFFECT; METABOLISM; STAINING;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HIV PROTEASE INHIBITORS; HUMANS; STAINING AND LABELING; TRITIUM;

EID: 77953725356     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq082     Document Type: Article

References (74)

1. Kinman LM, Worlein JM, Leigh J et al. HIV in central nervous system and behavioral development: an HIV-2287 macaque model of AIDS. AIDS 2004; 18: 1363-70.
2. Cavert W, Notermans DW, Staskus K et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276: 960-4.
3. Gomez E. Hidden HIV reservoirs: will eradication of the virus be possible? Newsline People AIDS Coalit N Y 1998: 18-9.
4. Pomerantz RJ. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. Biomed Pharmacother 2001; 55: 7-15.
5. Kinman L, Brodie SJ, Tsai CC et al. Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. J Acquir Immune Defic Syndr 2003; 34: 387-97.
6. Saksena NK, Potter SJ. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. AIDS Rev 2003; 5: 3-18.
7. Bowman MC, Archin NM, Margolis DM. Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev Mol Med 2009; 11: e6.
8. Kim AE, Dintaman JM, Waddell DS et al. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998; 286: 1439-45.
9. Gutmann H, Fricker G, Drewe J et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999; 56: 383-9.
10. Jones K, Bray PG, Khoo SH et al. P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 2001; 15: 1353-8.
11. Huisman MT, Smit JW, Crommentuyn KM et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002; 16: 2295-301.
12. Woodahl EL, Yang Z, Bui T et al. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS 2005; 19: 1617-25.
13. Janneh O, Owen A, Chandler B et al. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 2005; 19: 2097-102.
14. Janneh O, Chandler B, Hartkoorn R et al. Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2009; 64: 1002-7.
15. Kwan WS, Janneh O, Hartkoorn R et al. Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. Br J Clin Pharmacol 2009; 68: 375-80.
16. Su Y, Zhang X, Sinko PJ. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of saquinavir in Hep G2 cells. Mol Pharm 2004; 1: 49-56.
17. Janneh O, Hartkoorn RC, Jones E et al. Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. Br J Pharmacol 2008; 155: 875-83.
18. Ford J, Khoo SH, Back DJ. The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother 2004; 54: 982-90.
19. Janneh O, Jones E, Chandler B et al. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2007; 60: 987-93.
20. Winzer R, Langmann P, Zilly M et al. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res 2003; 8: 531-4.
21. Elens L, Yombi JC, Lison D et al. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics 2009; 10: 1589-97.
22. Mrozikiewicz PM, Seremak-Mrozikiewicz A, Semczuk A et al. The significance of C3435T point mutation of the MDR1 gene in endometrial cancer. Int J Gynecol Cancer 2007; 17: 728-31.
23. Vicente J, Sinues B, Fanlo A et al. Polymorphism C3435T of the MDR1 gene in Central Americans and Spaniards. Mol Biol Rep 2008; 35: 473-8.
24. Hemauer SJ, Nanovskaya TN, Abdel-Rahman SZ et al. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem Pharmacol 2010; 79: 921-5.
25. Haenisch S, May K, Wegner D et al. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics 2008; 18: 357-65.
26. Yin JY, Huang Q, Yang Y et al. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics 2009; 19: 206-16.
27. La Porte CJ, Li Y, Beique L et al. The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. Clin Pharmacol Ther 2007; 82: 389-95.
28. Ma Q, Brazeau D, Zingman BS et al. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics 2007; 8: 227-35.
29. Estrela Rde C, Ribeiro FS, Barroso PF et al. ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy. Pharmacogenomics 2009; 10: 311-8.
30. Rodriguez Novoa S, Barreiro P, Rendon A et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006; 42: 291-5.
31. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275-91.
32. Sabbatani S, Legnani G, Fulgaro C. First evaluations of LPV/RTV (Kaletra) efficacy on HIV-positive patients treated with multiple drugs. Infez Med 2003; 11: 18-24.
33. Johnson M, Grinsztejn B, Rodriguez C et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20: 711-8.
34. Avihingsanon A, van der Lugt J, Kerr SJ et al. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther 2009; 85: 402-8.
35. Ribera E, Azuaje C, Lopez RM et al. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 2006; 20: 1131-9.
36. von Hentig N, Muller A, Rottmann Cet al. Pharmacokineticsof saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. Antimicrob Agents Chemother 2007; 51: 1431-9.
37. Choi H, Jeong SJ, Lee HS et al. Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy. J Korean Med Sci 2008; 23: 737-9.
38. van Heeswijk RP, Veldkamp A, Mulder JW et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2001; 6: 201-29.
39. Polli JW, Jarrett JL, Studenberg SD et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 1999; 16: 1206-12.
40. Choo EF, Leake B, Wandel C et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28: 655-60.
41. Edwards JE, Brouwer KR, McNamara PJ. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Antimicrob Agents Chemother 2002; 46: 2284-6.
42. Savolainen J, Edwards JE, Morgan ME et al. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats. Drug Metab Dispos 2002; 30: 479-82.
43. Huisman MT, Smit JW, Wiltshire HR et al. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001; 59: 806-13.
44. van Praag RM, Weverling GJ, Portegies P et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000; 14: 1187-94.
45. Tayrouz Y, Ganssmann B, Ding R et al. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther 2001; 70: 405-14.
46. Ford J, Meaden ER, Hoggard PG et al. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. J Antimicrob Chemother 2003; 52: 354-8.
47. Chandler B, Almond L, Ford J et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 2003; 33: 551-6.
48. Zastre JA, Chan GN, Ronaldson PT et al. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res 2009; 87: 1023-36.
49. Huang L, Wring SA, Woolley JL et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001; 29: 754-60.
50. Dixit V, Hariparsad N, Li F et al. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007; 35: 1853-9.
51. Perloff MD, Von Moltke LL, Marchand JE et al. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 2001; 90: 1829-37.
52. Gupta A, Zhang Y, Unadkat JD et al. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 2004; 310: 334-41.
53. Storch CH, Theile D, Lindenmaier H et al. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007; 73: 1573-81.
54. Mistry P, Stewart AJ, Dangerfield W et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001; 61: 749-58.
55. Pick A, Muller H, Wiese M. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). Bioorg Med Chem 2008; 16: 8224-36.
56. Kuhnle M, Egger M, Muller C et al. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem 2009; 52: 1190-7.
57. Dallas S, Zhu X, Baruchel S et al. Functional expression of the multidrug resistance protein 1 in microglia. J Pharmacol Exp Ther 2003; 307: 282-90.
58. Honda Y, Ushigome F, Koyabu N et al. Effects of grapefruit juice and orange juice components on P-glycoprotein-and MRP2-mediated drug efflux. Br J Pharmacol 2004; 143: 856-64.
59. Park S, Sinko PJ. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exp Ther 2005; 312: 1249-56.
60. Perloff MD, von Moltke LL, Fahey JM et al. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 2000; 14: 1287-9.
61. Hennessy M, Clarke S, Spiers JP et al. Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients. Antivir Ther 2004; 9: 115-22.
62. Perloff MD, von Moltke LL, Fahey JM et al. Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J Pharm Pharmacol 2007; 59: 947-53.
63. Usansky HH, Hu P, Sinko PJ. Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats. Drug Metab Dispos 2008; 36: 863-9.
64. Knox TA, Oleson L, von Moltke LL et al. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr 2008.
65. Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Expert Opin Drug Metab Toxicol 2007; 3: 583-98.
66. Hennessy M, Kelleher D, Spiers JP et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002; 53: 75-82.
67. Patel J, Buddha B, Dey S et al. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 2004; 11: 262-77.
68. Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004; 24: 1732-47.
69. Culm-Merdek KE, von Moltke LL, Gan L et al. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther 2006; 79: 243-54.
70. Agarwal S, Pal D, Mitra AK. Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm 2007; 339: 139-47.
71. van der Sandt IC, Vos CM, Nabulsi L et al. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS 2001; 15: 483-91.
72. Meaden ER, Hoggard PG, Newton P et al. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother 2002; 50: 583-8.
73. Bousquet L, Roucairol C, Hembury A et al. Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier. AIDS Res Hum Retroviruses 2008; 24: 1147-54.
74. Perloff ES, Duan SX, Skolnik PR et al. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 2005; 33: 764-70.